Juliann Chmielecki, Ph.D. - Publications

2011 Weill Cornell Medical College, New York, NY, United States 
Oncology, Molecular Biology, Biochemistry

52 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Jonsson P, Lin AL, Young RJ, DiStefano NM, Hyman DM, Li BT, Berger MF, Zehir A, Ladanyi M, Solit DB, Arnold AG, Stadler ZK, Mandelker D, Goldberg ME, Chmielecki J, et al. Genomic correlates of disease progression and treatment response in prospectively characterized gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31263031 DOI: 10.1158/1078-0432.Ccr-19-0032  0.32
2017 Parachoniak CA, Rankin A, Gaffney B, Hartmaier R, Spritz D, Erlich RL, Miller VA, Morosini D, Stephens P, Ross JS, Keech J, Chmielecki J. Exceptional Durable Response to Everolimus in a Patient with Biphenotypic Breast Cancer Harboring an STK11 Variant. Cold Spring Harbor Molecular Case Studies. PMID 28550065 DOI: 10.1101/mcs.a000778  0.32
2017 Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, Huang F, He Y, Sun J, Tabori U, Kennedy M, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Medicine. 9: 34. PMID 28420421 DOI: 10.1186/S13073-017-0424-2  0.32
2017 Hartmaier RJ, Charo J, Fabrizio D, Goldberg ME, Albacker LA, Pao W, Chmielecki J. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies. Genome Medicine. 9: 16. PMID 28231819 DOI: 10.1186/s13073-017-0408-2  0.92
2017 Chmielecki J, Bailey M, He J, Elvin J, Vergilio JA, Ramkissoon S, Suh J, Frampton GM, Sun JX, Morley S, Spritz D, Ali S, Gay L, Erlich RL, Ross JS, et al. Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. Cancer Research. PMID 28069802 DOI: 10.1158/0008-5472.CAN-16-1106  0.32
2016 Meletath SK, Pavlick D, Brennan T, Hamilton R, Chmielecki J, Elvin JA, Palma N, Ross JS, Miller VA, Stephens PJ, Snipes G, Rajaram V, Ali SM, Melguizo-Gavilanes I. Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 1345-1350. PMID 27799506 DOI: 10.6004/Jnccn.2016.0145  0.32
2016 Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, Bose R, Vergilio JA, Suh J, Yelensky R, Lipson D, Chmielecki J, Waintraub S, Leyland-Jones B, Miller VA, et al. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies. Cancer. PMID 27284958 DOI: 10.1002/cncr.30102  0.92
2016 Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, et al. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. The Oncologist. PMID 27245569 DOI: 10.1634/theoncologist.2015-0497  0.92
2016 Heilmann AM, Subbiah V, Wang K, Sun JX, Elvin JA, Chmielecki J, Sherman SI, Murthy R, Busaidy NL, Subbiah I, Yelensky R, Nangia C, Vergilio JA, Khan SA, Erlich RL, et al. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology. PMID 27207748 DOI: 10.1159/000445978  0.92
2016 Suh JH, Johnson A, Albacker L, Wang K, Chmielecki J, Frampton G, Gay L, Elvin JA, Vergilio JA, Ali S, Miller VA, Stephens PJ, Ross JS. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. The Oncologist. PMID 27151654 DOI: 10.1634/theoncologist.2016-0030  0.92
2016 Chung JH, Sanford E, Johnson A, Klempner SJ, Schrock AB, Palma NA, Erlich RL, Frampton GM, Chalmers ZR, Vergilio J, Rubinson DA, Sun JX, Chmielecki J, Yelensky R, Suh JH, et al. Comprehensive Genomic Profiling of Anal Squamous Cell Carcinoma Reveals Distinct Genomically Defined Classes. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 27052656 DOI: 10.1093/annonc/mdw152  0.92
2016 Foster SA, Whalen DM, Özen A, Wongchenko MJ, Yin J, Yen I, Schaefer G, Mayfield JD, Chmielecki J, Stephens PJ, Albacker LA, Yan Y, Song K, Hatzivassiliou G, Eigenbrot C, et al. Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2. Cancer Cell. PMID 26996308 DOI: 10.1016/J.Ccell.2016.02.010  0.92
2016 Schrock AB, Frampton GM, Herndon D, Greenbowe J, Wang K, Lipson D, Yelensky R, Chalmers Z, Chmielecki J, Elvin JA, Wollner M, Dvir A, Soussan-Guttman L, Bordonii R, Peled N, et al. Comprehensive Genomic Profiling Identifies Frequent Drug Sensitive EGFR Exon 19 Deletions in NSCLC Not Identified by Prior Molecular Testing. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26933124 DOI: 10.1158/1078-0432.CCR-15-1668  0.92
2015 Ali SM, Pal SK, Wang K, Palma NA, Sanford E, Bailey M, He J, Elvin JA, Chmielecki J, Squillace R, Dow E, Morosini D, Buell J, Yelensky R, Lipson D, et al. Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations. The Oncologist. PMID 26670666 DOI: 10.1634/theoncologist.2015-0241  0.92
2015 Williams CB, McMahon C, Ali SM, Abramovitz M, Williams KA, Klein J, McKean H, Yelensky R, George TJ, Elvin JA, Soman S, Lipson D, Chmielecki J, Morosini D, Miller VA, et al. A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. Oncotargets and Therapy. 8: 3561-3564. PMID 26664139 DOI: 10.2147/OTT.S90766  0.92
2015 Ross JS, Ali SM, Wang K, Khaira D, Palma NA, Chmielecki J, Palmer GA, Morosini D, Elvin JA, Fernandez SV, Miller VA, Stephens PJ, Cristofanilli M. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. Breast Cancer Research and Treatment. PMID 26458824 DOI: 10.1007/s10549-015-3592-z  0.92
2015 Wang K, Johnson A, Ali SM, Klempner SJ, Bekaii-Saab T, Vacirca JL, Khaira D, Yelensky R, Chmielecki J, Elvin JA, Lipson D, Miller VA, Stephens PJ, Ross JS. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. The Oncologist. PMID 26336083 DOI: 10.1634/theoncologist.2015-0156  0.92
2015 Ross JS, Wang K, Chmielecki J, Gay L, Johnson A, Chudnovsky J, Yelensky R, Lipson D, Ali SM, Elvin JA, Vergilio JA, Roels S, Miller VA, Nakamura BN, Gray A, et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. International Journal of Cancer. Journal International Du Cancer. PMID 26314551 DOI: 10.1002/ijc.29825  0.92
2015 Disel U, Germain A, Yilmazel B, Abali H, Bolat FA, Yelensky R, Elvin JA, Lipson D, Chmielecki J, Wang K, Stephens PJ, Ross JS, Miller VA, Ali SM, George TJ. Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification. Oncoscience. 2: 581-4. PMID 26244165 DOI: 10.18632/oncoscience.175  0.92
2015 Klempner SJ, Bazhenova LA, Braiteh FS, Nikolinakos PG, Gowen K, Cervantes CM, Chmielecki J, Greenbowe JR, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Lung Cancer (Amsterdam, Netherlands). 89: 357-9. PMID 26187428 DOI: 10.1016/j.lungcan.2015.06.021  0.92
2015 Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, Palmer G, Yelensky R, Lipson DM, Chmielecki J, Erlich RL, Rankin AN, Ali SM, Elvin JA, Morosini D, et al. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. Jama Oncology. 1: 40-9. PMID 26182302 DOI: 10.1001/jamaoncol.2014.216  0.92
2015 Crago AM, Chmielecki J, Rosenberg M, O'Connor R, Byrne C, Wilder FG, Thorn K, Agius P, Kuk D, Socci ND, Qin LX, Meyerson M, Hameed M, Singer S. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes, Chromosomes & Cancer. PMID 26171757 DOI: 10.1002/Gcc.22272  0.92
2015 Pal SK, Choueiri TK, Wang K, Khaira D, Karam JA, Van Allen E, Palma NA, Stein MN, Johnson A, Squillace R, Elvin JA, Chmielecki J, Yelensky R, Yakirevich E, Lipson D, et al. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. European Urology. PMID 26149668 DOI: 10.1016/j.eururo.2015.06.019  0.92
2015 Subbiah V, McMahon C, Patel S, Zinner R, Silva EG, Elvin JA, Subbiah IM, Ohaji C, Ganeshan DM, Anand D, Levenback CF, Berry J, Brennan T, Chmielecki J, Chalmers ZR, et al. STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. Journal of Hematology & Oncology. 8: 66. PMID 26062823 DOI: 10.1186/s13045-015-0160-2  0.92
2015 Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SI, Salgia R, Brennan T, Chalmers ZR, et al. Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors. Cancer Discovery. PMID 25971938 DOI: 10.1158/2159-8290.Cd-15-0285  0.92
2015 Ali SM, Sanford EM, Klempner SJ, Rubinson DA, Wang K, Palma NA, Chmielecki J, Yelensky R, Palmer GA, Morosini D, Lipson D, Catenacci DV, Braiteh F, Erlich R, Stephens PJ, et al. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. The Oncologist. 20: 499-507. PMID 25882375 DOI: 10.1634/theoncologist.2014-0378  0.92
2015 Chalmers ZR, Ali SM, Ohgami RS, Campregher PV, Frampton GM, Yelensky R, Elvin JA, Palma NA, Erlich R, Vergilio JA, Chmielecki J, Ross JS, Stephens PJ, Hermann R, Miller VA, et al. Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy. Blood Cancer Journal. 5: e278. PMID 25658984 DOI: 10.1038/bcj.2014.95  0.92
2015 Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, Seepo S, Meyerson M, Pass HI. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Research. 75: 264-9. PMID 25488749 DOI: 10.1158/0008-5472.Can-14-1008  0.92
2015 Chmielecki J, Ross JS, Wang K, Frampton GM, Palmer GA, Ali SM, Palma N, Morosini D, Miller VA, Yelensky R, Lipson D, Stephens PJ. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. The Oncologist. 20: 7-12. PMID 25480824 DOI: 10.1634/theoncologist.2014-0234  0.92
2014 Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD, Chen J, Robinson HE, Shim HS, Chmielecki J, Pao W, Engelman JA, Iafrate AJ, Le LP. Anchored multiplex PCR for targeted next-generation sequencing. Nature Medicine. 20: 1479-84. PMID 25384085 DOI: 10.1038/nm.3729  0.92
2014 Chmielecki J, Hutchinson KE, Frampton GM, Chalmers ZR, Johnson A, Shi C, Elvin J, Ali SM, Ross JS, Basturk O, Balasubramanian S, Lipson D, Yelensky R, Pao W, Miller VA, et al. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. Cancer Discovery. 4: 1398-405. PMID 25266736 DOI: 10.1158/2159-8290.CD-14-0617  0.92
2014 . Comprehensive molecular profiling of lung adenocarcinoma. Nature. 511: 543-50. PMID 25079552 DOI: 10.1038/Nature13385  0.92
2014 Ross JS, Wang K, Rand JV, Gay L, Presta MJ, Sheehan CE, Ali SM, Elvin JA, Labrecque E, Hiemstra C, Buell J, Otto GA, Yelensky R, Lipson D, Morosini D, ... Chmielecki J, et al. Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies. Journal of Clinical Pathology. 67: 968-73. PMID 25078331 DOI: 10.1136/jclinpath-2014-202514  0.92
2014 Sharman JP, Chmielecki J, Morosini D, Palmer GA, Ross JS, Stephens PJ, Stafl J, Miller VA, Ali SM. Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma. Clinical Lymphoma, Myeloma & Leukemia. 14: e161-3. PMID 24997557 DOI: 10.1016/j.clml.2014.06.004  0.92
2014 Ross JS, Wang K, Elkadi OR, Tarasen A, Foulke L, Sheehan CE, Otto GA, Palmer G, Yelensky R, Lipson D, Chmielecki J, Ali SM, Elvin J, Morosini D, Miller VA, et al. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. Journal of Clinical Pathology. 67: 772-6. PMID 24978188 DOI: 10.1136/jclinpath-2014-202447  0.92
2014 Brooks AN, Choi PS, de Waal L, Sharifnia T, Imielinski M, Saksena G, Pedamallu CS, Sivachenko A, Rosenberg M, Chmielecki J, Lawrence MS, DeLuca DS, Getz G, Meyerson M. A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. Plos One. 9: e87361. PMID 24498085 DOI: 10.1371/Journal.Pone.0087361  0.92
2014 Chmielecki J, Meyerson M. DNA sequencing of cancer: what have we learned? Annual Review of Medicine. 65: 63-79. PMID 24274178 DOI: 10.1146/Annurev-Med-060712-200152  0.92
2013 Chmielecki J, Crago AM, Rosenberg M, O'Connor R, Walker SR, Ambrogio L, Auclair D, McKenna A, Heinrich MC, Frank DA, Meyerson M. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nature Genetics. 45: 131-2. PMID 23313954 DOI: 10.1038/Ng.2522  0.92
2012 Foo J, Chmielecki J, Pao W, Michor F. Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 1583-93. PMID 22982659 DOI: 10.1097/Jto.0B013E31826146Ee  0.92
2012 Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proceedings of the National Academy of Sciences of the United States of America. 109: E2127-33. PMID 22773810 DOI: 10.1073/pnas.1203530109  0.92
2012 Chmielecki J, Pietanza MC, Aftab D, Shen R, Zhao Z, Chen X, Hutchinson K, Viale A, Kris MG, Stout T, Miller V, Rizvi N, Pao W. EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 434-42. PMID 22173702 DOI: 10.1097/JTO.0b013e31823c5aee  0.92
2012 Chmielecki J, Peifer M, Viale A, Hutchinson K, Giltnane J, Socci ND, Hollis CJ, Dean RS, Yenamandra A, Jagasia M, Kim AS, Davé UP, Thomas RK, Pao W. Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. Genes, Chromosomes & Cancer. 51: 54-65. PMID 21938754 DOI: 10.1002/gcc.20930  0.92
2011 Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5530-7. PMID 21775534 DOI: 10.1158/1078-0432.CCR-10-2571  0.92
2011 Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, Socci ND, Viale A, de Stanchina E, Ginsberg MS, Thomas RK, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Science Translational Medicine. 3: 90ra59. PMID 21734175 DOI: 10.1126/Scitranslmed.3002356  0.92
2011 Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, Pao W, Ladanyi M, Miller VA. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1616-22. PMID 21135146 DOI: 10.1158/1078-0432.CCR-10-2692  0.92
2010 Chmielecki J, Pao W. Highly active antitumor therapy (HAATT) for epidermal growth factor receptor-mutant lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5371-3. PMID 21062927 DOI: 10.1158/1078-0432.CCR-10-2405  0.92
2010 Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews. Cancer. 10: 760-74. PMID 20966921 DOI: 10.1038/nrc2947  0.92
2010 Chmielecki J, Peifer M, Jia P, Socci ND, Hutchinson K, Viale A, Zhao Z, Thomas RK, Pao W. Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. Nucleic Acids Research. 38: 6985-96. PMID 20587502 DOI: 10.1093/nar/gkq579  0.92
2009 Roovers K, Wagner S, Storbeck CJ, O'Reilly P, Lo V, Northey JJ, Chmielecki J, Muller WJ, Siegel PM, Sabourin LA. The Ste20-like kinase SLK is required for ErbB2-driven breast cancer cell motility. Oncogene. 28: 2839-48. PMID 19525980 DOI: 10.1038/onc.2009.146  0.92
2009 Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America. 106: 9435-40. PMID 19478061 DOI: 10.1073/Pnas.0900571106  0.92
2008 Northey JJ, Chmielecki J, Ngan E, Russo C, Annis MG, Muller WJ, Siegel PM. Signaling through ShcA is required for transforming growth factor beta- and Neu/ErbB-2-induced breast cancer cell motility and invasion. Molecular and Cellular Biology. 28: 3162-76. PMID 18332126 DOI: 10.1128/MCB.01734-07  0.92
2007 Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X, Pao W. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. Plos Medicine. 4: e294. PMID 17927446 DOI: 10.1371/journal.pmed.0040294  0.92
Show low-probability matches.